BRIEF-XORTX Therapeutics Inc Announces Launch Of XRX-026 Drug Development Program To Treat Gout
ReutersJan 6, 2025 11:03 PM
Jan 6 (Reuters) - XORTX Therapeutics Inc XRTX.V:
XORTX THERAPEUTICS INC: ANNOUNCES LAUNCH OF XRX-026 DRUG DEVELOPMENT PROGRAM TO TREAT GOUT
XORTX THERAPEUTICS INC: PROGRAM TO FOCUS ON TREATMENT OF INDIVIDUALS WHO HAVE GOUT AND ARE INTOLERANT TO ALLOPURINOL
Source text: [ID:n0001171843-25-000052]
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Investing in Industrials Stocks
TradingKey - Industrials are having a remarkable 2025 recovery, quietly but powerfully. No longer a defensively minded, yield-driven sector, they are riding waves of structural change from geopolitics and AI infrastructure to the great global supply chain reshore. While the S&P 500 continues to...TradingKey
13 hours ago
U.S. GDP, PCE, and Fed Rate Decision Commentary: Will U.S. Stocks Continue to Rise?
TradingKey - On 30–31 July 2025, the United States released its latest GDP and PCE data, while the Federal Reserve announced its interest rate decision during the same period.TradingKey
18 hours ago
Apple Q3 FY2025 Earnings Review: Strong iPhone Performance and AI Momentum Amid Tariff Challenges
TradingKey - Apple Inc. (NASDAQ: AAPL) released its Q3 FY2025 earnings on July 31, 2025, after market close, delivering results that surpassed expectations, driven by robust iPhone sales and strong Services growth. Despite a slight dip in initial after-hours trading, Apple’s stock rose 2%...TradingKey
20 hours ago
What to Expect From Meta Q2 Earnings: AI Push, Ad Strength — But Can Profitability Hold?
TradingKey - Meta Platforms (META), the parent company of Facebook, Instagram, and WhatsApp, will release its Q2 2025 earnings after the U.S. market close on Wednesday, July 30. After nine consecutive quarters of beating expectations, analysts expect another strong performance — driven by AI-poweredTradingKey
Tue, Jul 29
[IN-DEPTH ANALYSIS] UnitedHealth (UNH): Can the Healthcare Giant Recover After Its Epic Collapse?
Once a Wall Street sweetheart, UnitedHealth Group (UNH) dominated the US healthcare industry with its unbeatable vertical empire, spanning insurance, clinics, pharmacies, and data analytics.TradingKey
Mon, May 26
.jpg)
